지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한정신약물학회 Clinical Psychopharmacology and Neuroscience Clinical Psychopharmacology and Neuroscience 제10권 제2호
- 발행연도
- 2012.1
- 수록면
- 71 - 77 (7page)
이용수
초록· 키워드
오류제보하기
Treatment with several antipsychotic drugs can result in weight gain, which may lead to further morbidity such as type 2 diabetes and cardiovascular disease via the development of metabolic syndrome. These important and problematic metabolic consequences of antipsychotic drug treatment probably reflect a pharmacological disruption of the mechanisms involved in control of food intake and body weight. The extent of weight gain following antipsychotic drug treatment shows substantial variability between individuals, due in part to genetic factors. Common functional polymorphisms in many candidate genes implicated in the control of body weight and various aspects of energy and lipid metabolism have been investigated for association with weight gain in subjects receiving antipsychotic drug treatment, and with metabolic pathology in chronic schizophrenia. Perhaps the strongest and most replicated findings are the associations with promoter polymorphisms in the 5-HT2C receptor and leptin genes, although many other possible genetic risk factors, including polymorphisms in the fat mass and obesity associated (FTO)gene and genes for the alpha2A adrenoceptor and melanocortin4 receptor, have been reported. Genome-wide association studies (GWAS) have also addressed antipsychotic-induced weight gain and other indicators of metabolic disturbances. However there is as yet little consistency between these studies or between GWAS and classical candidate gene approaches. Identifying common genetic factors associated with drug-induced weight gain and its metabolic consequences may provide opportunities for personalized medicine in the predictive assessment of metabolic risk as well as indicating underlying physiological mechanisms.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Allison DB / 1999 / Antipsychotic-induced weight gain: a comprehensive research synthesis / Am J Psychiatry 156 : 1686 ~ 1696
Arranz MJ / 2007 / Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research / Mol Psychiatry 12 : 707 ~ 747
Brandl EJ / 2012 / Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain / Prog Neuropsychopharmacol Biol Psychi
Ellingrod VL / 2005 / Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine / Am J Med Genet B Neuropsychiatr Genet 134B : 76 ~ 78
Gebhardt S / 2010 / Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study / J Clin Pharm Ther 35 : 207 ~ 211
Arranz MJ / 2007 / Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research / Mol Psychiatry 12 : 707 ~ 747
Brandl EJ / 2012 / Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain / Prog Neuropsychopharmacol Biol Psychi
Ellingrod VL / 2005 / Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine / Am J Med Genet B Neuropsychiatr Genet 134B : 76 ~ 78
Gebhardt S / 2010 / Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study / J Clin Pharm Ther 35 : 207 ~ 211
이 논문의 저자 정보
최근 본 자료
댓글(0)
0